Loading...
Loading...
340B Health (340B Coalition)
The premier 340B-specific gathering. Manufacturer dispute strategy, contract pharmacy compliance, federal litigation updates (4th Circuit ruling), HRSA audit prep.
With Lilly/Novo claims-data mandates active and 4th Circuit ruling in favor of providers, 340B is in active flux. Critical for FQHC pharmacy directors.
Attendees
700
FQHC %
75%
TAM
$200K
ROI
moderate
“340B is 30%+ of FQHC margin. With Lilly/Novo claims-data mandates active and 4th Circuit ruling, this is the conference where 340B strategy gets debated. Best for thought leadership on 340B revenue protection.”